These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 22099308)

  • 1. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
    Popovic R; Martinez-Garcia E; Giannopoulou EG; Zhang Q; Zhang Q; Ezponda T; Shah MY; Zheng Y; Will CM; Small EC; Hua Y; Bulic M; Jiang Y; Carrara M; Calogero RA; Kath WL; Kelleher NL; Wang JP; Elemento O; Licht JD
    PLoS Genet; 2014 Sep; 10(9):e1004566. PubMed ID: 25188243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin.
    Sankaran SM; Wilkinson AW; Elias JE; Gozani O
    J Biol Chem; 2016 Apr; 291(16):8465-74. PubMed ID: 26912663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
    Zheng Y; Fornelli L; Compton PD; Sharma S; Canterbury J; Mullen C; Zabrouskov V; Fellers RT; Thomas PM; Licht JD; Senko MW; Kelleher NL
    Mol Cell Proteomics; 2016 Mar; 15(3):776-90. PubMed ID: 26272979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISWI chromatin remodeling complexes recruit NSD2 and H3K36me2 in pericentromeric heterochromatin.
    Goto N; Suke K; Yonezawa N; Nishihara H; Handa T; Sato Y; Kujirai T; Kurumizaka H; Yamagata K; Kimura H
    J Cell Biol; 2024 Aug; 223(8):. PubMed ID: 38709169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
    Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
    Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
    García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
    Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSD2 as a Promising Target in Hematological Disorders.
    Azagra A; Cobaleda C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma.
    Chong PSY; Chooi JY; Lim SLJ; Chung TH; Brunmeir R; Leow ACY; Toh SHM; Balan K; Azaman MIB; Wu Z; Subramaniam N; Vardy LA; Chng WJ
    Haematologica; 2024 Jun; 109(6):1893-1908. PubMed ID: 38124661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
    Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
    Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
    Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
    Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
    Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
    Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36.
    Poulin MB; Schneck JL; Matico RE; McDevitt PJ; Huddleston MJ; Hou W; Johnson NW; Thrall SH; Meek TD; Schramm VL
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1197-201. PubMed ID: 26787850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.